Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 5, 2026

Wells Fargo Stock Jumps Nearly 19% in 3 Months: Right Time to Buy?

View original at finance.yahoo.com
Wells Fargo Stock Jumps Nearly 19% in 3 Months: Right Time to Buy? Shares of Wells Fargo & Company WFC have gained 18.6% in the past three months compared with the industry’s rise of 9.1%…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Wells Fargo expects 2025 NII to be in line with 2024 NII of $47.7 billion

    80% confidence

  • Wells Fargo targets up to $10 billion in annual cost cuts

    80% confidence

  • Wells Fargo signaled workforce could shrink in 2026 as part of push to improve efficiency and incorporate AI

    80% confidence

  • Wells Fargo raised medium-term ROTCE target to 17-18% from earlier 15%

    80% confidence

  • Wells Fargo carries Zacks Rank #2 (Buy)

    80% confidence

  • Wells Fargo expects to achieve $15 billion in gross expense savings by end of 2025

    80% confidence

  • Zacks Consensus Estimate for WFC 2025 earnings indicates 16.9% rally

    80% confidence

  • Wells Fargo plans to introduce AI gradually over next year and continue expanding use beyond 2026

    80% confidence

  • By end of 2025, slightly more than half of branch network expected to be refreshed

    80% confidence

  • Zacks Consensus Estimate for WFC 2026 sales suggests 5.4% growth

    80% confidence

  • Zacks Consensus Estimate for WFC 2026 earnings indicates 11.7% rally

    80% confidence

  • Wells Fargo stock worth investing in now for solid long-term returns

    80% confidence

  • Management characterized AI transition as a 'positive reality' suggesting AI-enabled efficiencies will support long-term operational improvements

    80% confidence

  • Zacks Consensus Estimate for WFC 2025 sales suggests 2.1% growth

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
Wells Fargo Stock Jumps Nearly 19% in 3 Months: Right Time to Buy? — Source | Via News | Finance Via News